Peripheral Blood Eosinophil as a Predictor of Clinical Outcomes in Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Cross-Sectional Study From a Tertiary Care Center in South India

外周血嗜酸性粒细胞作为慢性阻塞性肺疾病急性加重期临床结局的预测指标:来自印度南部一家三级医疗中心的横断面研究

阅读:1

Abstract

Aim and objective To evaluate the relationship between peripheral blood eosinophil levels (>5% at admission) and clinical outcomes, including ICU admission, duration of hospitalization, need for mechanical ventilation, and corticosteroid responsiveness, in patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) at Sree Balaji Medical College and Hospital, Chennai. Methods A total of 120 patients aged >45 years with AECOPD were enrolled in this study. Peripheral blood eosinophil percentage at the time of admission was recorded for all participants. Based on eosinophil levels, patients were categorized into two groups: eosinophilic (>5%) and non-eosinophilic (≤5%). Clinical outcomes, including ICU admission, duration of hospital stay, requirement for mechanical ventilation, and corticosteroid use, were analyzed. Statistical analysis was performed using the chi-square test and regression analysis to determine associations between eosinophil levels and clinical parameters. Results Patients in the non-eosinophilic group demonstrated significantly higher rates of ICU admissions (21.7% vs. 9.4%, p = 0.018), longer hospital stays (7.9 ± 2.4 vs. 5.6 ± 1.9 days, p = 0.003), and greater need for invasive ventilation (13.3% vs. 4.6%, p = 0.024). Corticosteroid usage was also notably higher in the non-eosinophilic group (73.3% vs. 42.1%, p < 0.001). Although mortality was slightly elevated in the non-eosinophilic group (5.7% vs. 2.1%), the difference was not statistically significant (p = 0.28). Conclusion Peripheral blood eosinophil count >5% is associated with favorable clinical outcomes in patients hospitalized with AECOPD. As a cost-effective and readily available biomarker, eosinophil levels may aid in stratifying patients and guiding personalized corticosteroid therapy during exacerbations.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。